BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is a publicly traded the market company. As of October 13, 2026, BBOT trades at $3.25 with a market cap of $265.38M and a P/E ratio of -0.85. BBOT moved -1.66% today. Year to date, BBOT is -73.96%; over the trailing twelve months it is -72.42%. Its 52-week range spans $3.23 to $14.87. Analyst consensus is strong buy with an average price target of $21.00. Rallies surfaces BBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BridgeBio Oncology Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4): BridgeBio Oncology Therapeutics reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
| Metric | Value |
|---|---|
| Price | $3.25 |
| Market Cap | $265.38M |
| P/E Ratio | -0.85 |
| EPS | $-4.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.87 |
| 52-Week Low | $3.23 |
| Volume | 190.05K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-134.04M |
| Gross Margin | 0.00% |
9 analysts cover BBOT: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $21.00.